80 related articles for article (PubMed ID: 19377509)
1. Ets-1 p27: a novel Ets-1 isoform with dominant-negative effects on the transcriptional properties and the subcellular localization of Ets-1 p51.
Laitem C; Leprivier G; Choul-Li S; Begue A; Monte D; Larsimont D; Dumont P; Duterque-Coquillaud M; Aumercier M
Oncogene; 2009 May; 28(20):2087-99. PubMed ID: 19377509
[TBL] [Abstract][Full Text] [Related]
2. Caspase cleavage of Ets-1 p51 generates fragments with transcriptional dominant-negative function.
Choul-Li S; Leroy C; Leprivier G; Laitem C; Tulasne D; Aumercier M
Biochem J; 2010 Feb; 426(2):229-41. PubMed ID: 20001963
[TBL] [Abstract][Full Text] [Related]
3. Splicing variant DeltaVII-Ets1 is downregulated in invasive Ets1-expressing breast cancer cells.
Ballschmieter P; Braig M; Lindemann RK; Nordheim A; Dittmer J
Int J Oncol; 2003 Apr; 22(4):849-53. PubMed ID: 12632078
[TBL] [Abstract][Full Text] [Related]
4. The caspase-generated cleavage product of Ets-1 p51 and Ets-1 p27, Cp17, induces apoptosis.
Choul-Li S; Tulasne D; Aumercier M
Biochem Biophys Res Commun; 2016 Nov; 480(1):1-7. PubMed ID: 27737766
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of effects caused by differentially spliced Ets-1 transcripts in fibroblasts.
Hahne JC; Fuchs T; Florin A; Edwards D; Pourtier A; Soncin F; Wernert N
Int J Oncol; 2011 Nov; 39(5):1073-82. PubMed ID: 21833469
[TBL] [Abstract][Full Text] [Related]
6. Functional analysis of a dominant-negative DeltaETS TEL/ETV6 isoform.
Sasaki K; Nakamura Y; Maki K; Waga K; Nakamura F; Arai H; Imai Y; Hirai H; Mitani K
Biochem Biophys Res Commun; 2004 May; 317(4):1128-37. PubMed ID: 15094386
[TBL] [Abstract][Full Text] [Related]
7. Ets-1 binds cooperatively to the palindromic Ets-binding sites in the p53 promoter.
Baillat D; Laitem C; Leprivier G; Margerin C; Aumercier M
Biochem Biophys Res Commun; 2009 Jan; 378(2):213-7. PubMed ID: 19022222
[TBL] [Abstract][Full Text] [Related]
8. Novel identification of the ETS-1 splice variants p42 and p27 in prostate cancer cell lines.
Adler D; Ochsenfahrt J; Fuchs K; Wernert N
Oncol Rep; 2012 May; 27(5):1321-4. PubMed ID: 22307076
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis of a PDEF Ets transcription factor-interacting protein complex.
Cho JY; Lee M; Ahn JM; Park ES; Cho JH; Lee SJ; Kim BG; Heo SH; Park HJ; Zerbini LF; Hwang D; Libermann TA
J Proteome Res; 2009 Mar; 8(3):1327-37. PubMed ID: 19203193
[TBL] [Abstract][Full Text] [Related]
10. Role of Ets-1 phosphorylation in the effector function of Th cells.
Grenningloh R; Miaw SC; Moisan J; Graves BJ; Ho IC
Eur J Immunol; 2008 Jun; 38(6):1700-5. PubMed ID: 18465773
[TBL] [Abstract][Full Text] [Related]
11. Characterization of an intramolecular protein-protein interaction in c-Ets1 and its viral homologue v-Ets.
Schmidt M; Schmidt AM; Dietl J; Kammerer U
Oncol Rep; 2007 Aug; 18(2):457-63. PubMed ID: 17611671
[TBL] [Abstract][Full Text] [Related]
12. Defining ETS transcription regulatory networks and their contribution to breast cancer progression.
Turner DP; Findlay VJ; Moussa O; Watson DK
J Cell Biochem; 2007 Oct; 102(3):549-59. PubMed ID: 17661355
[TBL] [Abstract][Full Text] [Related]
13. Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment.
Furlan A; Vercamer C; Desbiens X; Pourtier A
J Cell Physiol; 2008 Jun; 215(3):782-93. PubMed ID: 18181172
[TBL] [Abstract][Full Text] [Related]
14. Dominant-negative inhibition of Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and reveals differentially expressed Ets 1 target genes.
Sahin A; Vercamer C; Kaminski A; Fuchs T; Florin A; Hahne JC; Mattot V; Pourtier-Manzanedo A; Pietsch T; Fafeur V; Wernert N
Int J Oncol; 2009 Feb; 34(2):377-89. PubMed ID: 19148472
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer.
Lefter LP; Dima S; Sunamura M; Furukawa T; Sato Y; Abe M; Chivu M; Popescu I; Horii A
Cancer Gene Ther; 2009 Feb; 16(2):137-48. PubMed ID: 18772901
[TBL] [Abstract][Full Text] [Related]
16. Stromelysin-1 expression is activated in vivo by Ets-1 through palindromic head-to-head Ets binding sites present in the promoter.
Baillat D; Leprivier G; Régnier D; Vintonenko N; Bègue A; Stéhelin D; Aumercier M
Oncogene; 2006 Sep; 25(42):5764-76. PubMed ID: 16652151
[TBL] [Abstract][Full Text] [Related]
17. Ets-1 p51 and p42 isoforms differentially modulate Stromelysin-1 promoter according to induced DNA bend orientation.
Leprivier G; Baillat D; Begue A; Hartmann B; Aumercier M
Nucleic Acids Res; 2009 Jul; 37(13):4341-52. PubMed ID: 19465391
[TBL] [Abstract][Full Text] [Related]
18. Thymomegaly, microsplenia, and defective homeostatic proliferation of peripheral lymphocytes in p51-Ets1 isoform-specific null mice.
Higuchi T; Bartel FO; Masuya M; Deguchi T; Henderson KW; Li R; Muise-Helmericks RC; Kern MJ; Watson DK; Spyropoulos DD
Mol Cell Biol; 2007 May; 27(9):3353-66. PubMed ID: 17339335
[TBL] [Abstract][Full Text] [Related]
19. Efficient system for biotinylated recombinant Ets-1 production in Escherichia coli: a useful tool for studying interactions between Ets-1 and its partners.
Laitem C; Choul-Li S; Baillat D; Bègue A; Aumercier M
Protein Expr Purif; 2008 Nov; 62(1):53-63. PubMed ID: 18639639
[TBL] [Abstract][Full Text] [Related]
20. Analysis of mutations of the PITX2 transcription factor found in patients with Axenfeld-Rieger syndrome.
Footz T; Idrees F; Acharya M; Kozlowski K; Walter MA
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2599-606. PubMed ID: 19218601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
